The mission of Swiss Cure Pharma has always been to provide the highest quality, ethically obtained venoms from across the world, at fair prices, to support the development of life-saving antivenoms.
The launch of our new facility, coupled with a public serpentarium, underscores our commitment to furthering this goal by educating and inspiring future scientists. We strive to promote ongoing research into these animals and their venoms, champion the preservation of their natural habitats, and foster an understanding of the positive impact these creatures can have on human well-being.
Our Research
Our research primarily focuses on 3 areas most: The Goliath bird-eating spider, certain reptiles, and the Asian black forest scorpion. Our venoms, essentially modified saliva composed of various proteins and enzymes, are studied extensively. Traditional classifications of venom as either neurotoxic (affecting the nervous system) or hemotoxic (affecting tissue and blood) have evolved. Today, we understand that the spectrum of toxins includes mycotoxins, cardiotoxins, haemotoxins, neurotoxins, and many other types, with innumerable combinations thereof.
We are privileged to have Dr. Andrin Warner on our team, a descendant of the esteemed scientist Alfred Werner.
Dr. Warner, serving as the Production & Validation Officer at Swiss Cure Pharma.
Our Aim
Responding to the surging market demand, we have expanded our procurement operations for venomous animals globally, ensuring we offer the most competitive prices for these specimens. Recognizing the untapped potential of the Asian market, we've established our presence there to bridge the existing gap.
Our team in Asia is unparalleled, dedicated to assisting clients and strengthening our connections with both you and our network of country heads and esteemed dealers, renowned for their excellence.
Our acquisitions are conducted with strict adherence to the legal and regulatory frameworks of the respective countries, guaranteeing not only compliance but also the best possible rates for our partners.